Cumberland Q1 revenue $11.7M (+38% YoY), net profit $1.3M; DMD Phase II positive, Vibativ China OK

CUMBERLAND PHARMACEUTICALS INC

2025-Q1 EPS reported $0.08 revenue$11,713,055

Net revenue $11.7M vs $8.5M prior year, 38% increase.
Net income $1.3M; adjusted earnings $2.4M ($0.16/shr); operating cash flow $3.9M.
Positive Phase II data for ifetroban in Duchenne muscular dystrophy; FDA end-of-phase-II meeting planned.
Vibativ approved in China; launch expected by end of 2025.
Balance sheet: $15.1M cash, $5.2M drawn on credit facility; equity $28.7M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.